This Acquisition is the Start Sycamore BioPharma, Inc
."Company Prepares for Clinical Trials with Esteemed Addition: Dr. Mark T. Hamann, Endowed Chair of Drug Discovery and Biomedical Sciences at the MUSC College of Pharmacy"
Absolutely !! Paper is very possible with proper execution of the business plan and SEQUENTIAL growth quarter over quarter etc with products selling nationwide! This $BLEG could very well go from subs to paper aka $1 etc based on recurring revenues from variety of our acquisitions !